Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer

BACKGROUND. The CHER-LOB randomized phase II study showed that the combination of lapatinib and trastuzumab plus chemotherapy increases the pathologic complete remission (pCR) rate compared with chemotherapy plus either trastuzumab or lapatinib. A biomarker program was prospectively planned to ident...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Guarneri, Valentina, Dieci, Maria Vittoria, Frassoldati, Antonio, Maiorana, Antonino, Ficarra, Guido, Bettelli, Stefania, Tagliafico, Enrico, Bicciato, Silvio, Generali, Daniele Giulio, Cagossi, Katia, Bisagni, Giancarlo, Sarti, Samanta, Musolino, Antonino, Ellis, Catherine, Crescenzo, Rocco, Conte, PierFranco
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2015
Assuntos:
Breast Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4571802/
https://ncbi.nlm.nih.gov/pubmed/26245675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0138
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados